Cite
Restoring the Angiogenic Capacity of the Human Diabetic Adipose-derived mesenchymal stem cells Primed with Deferoxamine as a Hypoxia Mimetic Agent: Role of HIF-1α
MLA
Raziye Tajali, et al. “Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed with Deferoxamine as a Hypoxia Mimetic Agent: Role of HIF-1α.” Advanced Pharmaceutical Bulletin, vol. 13, no. 2, Mar. 2023, pp. 350–60. EBSCOhost, https://doi.org/10.34172/apb.2023.021.
APA
Raziye Tajali, Akram Eidi, Hosein Ahmadi Tafti, Abdolreza Pazouki, & Ali Mohammad Sharifi. (2023). Restoring the Angiogenic Capacity of the Human Diabetic Adipose-derived mesenchymal stem cells Primed with Deferoxamine as a Hypoxia Mimetic Agent: Role of HIF-1α. Advanced Pharmaceutical Bulletin, 13(2), 350–360. https://doi.org/10.34172/apb.2023.021
Chicago
Raziye Tajali, Akram Eidi, Hosein Ahmadi Tafti, Abdolreza Pazouki, and Ali Mohammad Sharifi. 2023. “Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed with Deferoxamine as a Hypoxia Mimetic Agent: Role of HIF-1α.” Advanced Pharmaceutical Bulletin 13 (2): 350–60. doi:10.34172/apb.2023.021.